top of page


FDA approves Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer
The FDA has approved Pfizer's Talzenna plus Xtandi for HRR-mutated metastatic hormone-sensitive prostate cancer, expanding the combination into an earlier treatment setting.

nuaxia
Oct 272 min read


China NMPA approves Foresee's Camcevi 42 mg six-month injection for advanced prostate cancer
China's NMPA has approved Foresee Pharmaceuticals' Camcevi 42 mg, a ready-to-use six-month leuprolide injection for adults with advanced prostate cancer.

nuaxia
Oct 132 min read


FDA expands Truqap approval to PTEN-deficient metastatic hormone-sensitive prostate cancer
The biomarker-selected regimen adds an AKT inhibitor to abiraterone and prednisone for adults with newly diagnosed metastatic disease whose tumours show PTEN deficiency.

nuaxia
Aug 62 min read


FDA approves Pluvicto with androgen receptor pathway inhibitor for PSMA-positive metastatic hormone-sensitive prostate cancer
The expanded indication moves radioligand therapy into an earlier stage of metastatic prostate cancer, providing an additional treatment option for eligible patients before progression to castration-resistant disease.

nuaxia
Aug 32 min read
bottom of page